This paper seeks to determine the effect of combination anti-PD-1 and antiretroviral therapy (ART) on people living with HIV (PLWH) with advanced gastric cancer. In our case, a PLWH with recurrent locally advanced gastric cancer was treated with anti-PD-1 inhibitor and ART. A significant reduction in tumor lesions (as demonstrated by contrast-enhanced CT imaging) and a better quality of life were achieved following treatment. There have been limited studies on the treatment of PLWH with advanced gastric cancer. Chemotherapy is most often used, however, with unsatisfactory outcomes. to date, there have been no published reports on the use of PD-1 inhibitors in PLWH with advanced gastric cancer. Our report provides a valuable reference for future management of such patients.
RobbinsHAPfeifferRMShielsMS, et al.Excess cancers among people living with HIV in the United States. J Natl Cancer Inst2015; 107(4): 8.
2.
ShielsMSEngelsEA. Evolving epidemiology of HIV associated malignancies. Curr Opin HIV AIDS2017; 12(1): 6–11.
3.
NagataNNishijimaTNiikuraR, et al.Increased risk of non-AIDS-defining cancers in Asian PLWH: a long-term cohort study. BMC Cancer2018; 18(1): 1066.
4.
PumpalovaYSSegallLFelliR, et al.The Impact of HIV on Non-AIDS defining gastrointestinal malignancies: a review. Semin Oncol2021; 48(3): 226–235. DOI: 10.1053/j.seminoncol.2021.09.001.
5.
AjaniJAD’AmicoTABentremDJ, et al.Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw2022; 20(2): 167–192. DOI: 10.6004/jnccn.2022.0008.
6.
BangY-JKangY-KCatenacciDV, et al.Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2019; 22(4): 828–837.
7.
CoghillAEShielsMSSunejaG, et al.Elevated cancerspecific mortality among PLWH in the United States. J Clin Oncol2015; 33: 2376–2383.
8.
JensenBEOetteMHaesJ, et al.HIV-associated gastrointestinal cancer. Oncol Res Treat2017; 40: 115–118.
9.
Joint United Nations Program On HIV/AIDS. Global HIV & AIDS statistics-FACT SHEET–WORLD AIDS DAY. Geneva: Joint United Nations Program On HIV/AIDS, 2021, pp. 1–6.
10.
RobbinsHAShielsMSPfeifferRM, et al.Epidemiologic contributions to recent cancer trends among people living with HIV in the United States. AIDS2014; 28(6): 881–890.
11.
GoehringerFBonnetFSalmonD, et al.Causes of death in HIV-positive individuals with immunovirologic success in a national prospective survey. AIDS Res Hum Retrovir2017; 33(2): 187–193. DOI: 10.1089/AID.2016.0222.
12.
ZhuWMaoYTangH, et al.Spectrum of malignancies among the population of adults living with HIV infection in China: a nationwide follow-up study, 2008–2011. PLoS One2019; 14(7): e0219766. DOI: 10.1371/journal.pone.0219766.
13.
BerrettaMDi FranciaRStanzioneB, et al.New treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy. Expet Opin Pharmacother2016; 17(18): 2391–2403. DOI: 10.1080/14656566.2016.1252332.
14.
XuQDongHWangZ, et al.Integration and viral oncogene expression of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma and gastric cancer. J Med Virol2023; 95(5): e28761. DOI: 10.1002/jmv.28761.
15.
GuihotAMarcelinAGMassianiMA, et al.Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol2018; 29(2): 517–518.
AmakiMYajimaKIwasakiY, et al.Administration of S-1 monotherapy as adjuvant chemotherapy in a patient with advanced gastric cancer with HIV infection. Gan To Kagaku Ryoho2016; 43(8): 995–997.
18.
ZhangJYZhangZWangXC, et al.PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood2007; 109(11): 4671–4678.
19.
MeierABagchiASidhuHK, et al.Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS2008; 22(5): 655–658.
20.
BowersNLHeltonESHuijbregtsRP, et al.Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog2014; 10(3): e1003993.
21.
LichterfeldMMouDLCungTDH, et al.Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood2008; 112(9): 3679–3687.
22.
FenwickCJooVJacquierP, et al.T-cell exhaustion in HIV infection. Immunol Rev2019; 292(1): 149–163.
23.
FromentinRDafonsecaSCostiniukCT, et al.PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nat Commun2019; 10(1): 814.
24.
UldrickTSGonçalvesPHAbdul-HayM, et al.Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study. JAMA Oncol2019; 5(9): 1332–1339.
25.
Blanch-LombarteOGálvezCRevolloB, et al.Enhancement of antiviral CD8+ T-cell responses and complete remission of metastatic melanoma in an HIV-1-infected subject treated with pembrolizumab. J Clin Med2019; 8(12): 2089.
26.
ProiettiISkrozaNMicheliniS, et al.Efficacy of nivolumab in HIV patient with melanoma brain metastases. AIDS2020; 34(9): 1433–1435.
27.
LavoleAMazieresJSchneiderS, et al.Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. Lung Cancer2021; 158: 146–150.
28.
LiDQHeCCXiaYX, et al.Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report. J Med Case Rep2018; 12(1): 104.
UldrickTSGonçalvesPHAbdul-HayM, et al.Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study. JAMA Oncol2019; 5(9): 1332–1339.
31.
CalkinsKLChanderGJoshuCE, et al.Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era. JAMA Oncol2020; 6(2): 227–235. DOI: 10.1001/jamaoncol.2019.4648.
32.
Ostios-GarciaLFaigJLeonardiGC, et al.Safety and efficacy of PD-1 inhibitors among HIV-positive patients with nonsmall cell lung cancer. J Thorac Oncol2018; 13(7): 1037–1042. DOI: 10.1016/j.jtho.2018.03.031.
33.
CookMRKimC. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol2019; 5(7): 1049–1054. DOI: 10.1001/jamaoncol.2018.6737.
34.
BarberDLWherryEJMasopustD, et al.Restoring function in exhausted CD8 T cells during chronic viral infection. Nature2006; 439(7077): 682–687.
35.
AmanchaPKHongJJRogersK, et al.In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. J Immunol2013; 191(12): 6060–6070.
36.
PinzoneMRFioricaFDi RosaM, et al.Non-AIDS-defining cancer s among people living with HIV. Eur Rev Med Pharmacol Sci2012; 16: 1377–1388.
37.
SimardEPEngelsEA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis2010; 51: 957–962.
